Chemical Structure (Dexlansoprazole 01)
Dexlansoprazole Capsule, Delayed Release
Product Images NDC 71335-3071
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Dexlansoprazole (NDC 71335-3071). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Dexlansoprazole 02)
This is a graph showing the plasma concentration (in ng/mL) of Dexlansoprazole at doses of 30 mg and 60 mg over a time period of 12, 16, and 20 hours. The concentrations range from 400 ng/mL to 1200 ng/mL.*
Label (Lbl713353071)
This is a description for Dexlansoprazole delayed-release capsules. Each capsule contains mg of Dexlansoprazole as enteric-coated granules. The usual dosage instructions should be followed as provided in the package insert. The medication guide should be dispensed to each patient by the pharmacist. The capsules should be stored at a temperature between 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The capsules should be repackaged in a tight, light-resistant container. Additionally, it is advised not to accept the product if the seal over the bottle opening is broken or missing.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
